Thanks for that post. Seems that there's a consensus regarding BG-12 becoming the biggest drug in MS in time. Aubagio doesn't look like a great choice considering its limited efficacy and tox and certainly not a 1st line drug. Alemtuzumab's safety issues will very much limit its use. No mention of Gilenya just next gen S1P1 compounds?
Market Data 
Markets 
AI
